| Title |
Clinical Management of Hereditary Breast Cancer Syndromes
|
|---|---|
| Published in |
Journal of Mammary Gland Biology and Neoplasia, March 2011
|
| DOI | 10.1007/s10911-011-9200-x |
| Pubmed ID | |
| Authors |
Amy S. Clark, Susan M. Domchek |
| Abstract |
Over the past 15 years there has been substantial improvement in the understanding of hereditary breast cancer. Germline genetic testing for mutations in BRCA1, BRCA2, PTEN and TP53 allows for the identification of individuals at increased risk for breast, ovarian and other cancers. Advances in screening, prevention and treatment have led to improved clinical management which is best defined for BRCA1 and BRCA2 mutation carriers. The addition of screening techniques such as breast magnetic resonance imaging has been shown to lead to earlier detection. Risk-reducing salpingo-oophorectomy leads to a reduction in the risk of both ovarian cancer and breast cancer and also is associated with an improvement in overall survival. BRCA1/2 mutation status may be applicable to systemic therapy decisions. Preclinical and early clinical research suggests that specific classes of chemotherapy may be more effective in mutation carriers. Finally, PARP inhibitors represent a novel therapeutic strategy that exploits the weaknesses of BRCA1/2-associated malignancies. |
Mendeley readers
The data shown below were compiled from readership statistics for 54 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 1 | 2% |
| Belgium | 1 | 2% |
| Unknown | 52 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 12 | 22% |
| Researcher | 9 | 17% |
| Student > Master | 8 | 15% |
| Student > Bachelor | 6 | 11% |
| Student > Doctoral Student | 4 | 7% |
| Other | 8 | 15% |
| Unknown | 7 | 13% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 16 | 30% |
| Agricultural and Biological Sciences | 13 | 24% |
| Biochemistry, Genetics and Molecular Biology | 7 | 13% |
| Nursing and Health Professions | 4 | 7% |
| Psychology | 2 | 4% |
| Other | 3 | 6% |
| Unknown | 9 | 17% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 May 2023.
All research outputs
#7,926,100
of 23,867,274 outputs
Outputs from Journal of Mammary Gland Biology and Neoplasia
#139
of 367 outputs
Outputs of similar age
#40,790
of 111,735 outputs
Outputs of similar age from Journal of Mammary Gland Biology and Neoplasia
#3
of 5 outputs
Altmetric has tracked 23,867,274 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 367 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.1. This one is in the 35th percentile – i.e., 35% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 111,735 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 26th percentile – i.e., 26% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 5 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.